Welcome to our dedicated page for Envveno Medical Corporation SEC filings (Ticker: NVNO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking the FDA journey of a novel venous valve is challenging鈥攅specially when enVVeno Medical Corporation鈥檚 pivotal trial data, PMA module responses, and financing details are scattered across dense SEC filings. If you have ever asked, 鈥淲here can I find the latest enVVeno Medical insider trading Form 4 transactions or the newest 8-K material events explained?鈥� this page solves that problem.
Stock Titan鈥檚 AI reads every submission the moment it hits EDGAR, then serves plain-English answers. Need the enVVeno Medical quarterly earnings report 10-Q filing without wading through accounting jargon? Our summaries highlight cash burn, R&D spend, and trial milestones. Wondering whether management is buying shares? AG真人官方-time alerts surface enVVeno Medical Form 4 insider transactions alongside context so you can gauge executive conviction.
All core documents are here and continuously updated:
- 10-K annual report鈥攇et the enVVeno Medical annual report 10-K simplified to understand long-term strategy and regulatory timelines.
- 10-Q quarterly updates鈥攃ompare enrollment progress with last quarter in seconds.
- 8-K releases鈥攕ee FDA feedback or financing announcements the moment they post.
- DEF 14A proxy鈥攅xplore enVVeno Medical proxy statement executive compensation details.
- Form 4鈥攖rack enVVeno Medical executive stock transactions Form 4 in real time.
From 鈥渦nderstanding enVVeno Medical SEC documents with AI鈥� to detailed enVVeno Medical earnings report filing analysis, our platform turns complex disclosures into actionable insight so you can focus on decisions鈥攏ot document hunts.
enVVeno Medical (NVNO) remains pre-revenue but is progressing its venous-valve pipeline while absorbing higher operating costs. In Q2-25 the company reported a net loss of $6.7 m (-0.33/sh), 35 % wider than Q2-24, driven by a 58 % jump in SG&A to $4.2 m (severance, stock comp and a $0.6 m reserve for prepaid clinical costs). R&D spend held essentially flat at $2.9 m.
Cash, cash equivalents and short-term Treasuries fell to $35.1 m from $43.2 m at YE-24; operating cash burn was $7.7 m for the first half. Working capital totals $32.6 m and management believes liquidity is adequate for 鈮�12 months, but it forecasts quarterly burn to rise to $5-7 m as trials advance.
- Pipeline: VenoValve PMA filing completed Nov-24 and is under FDA breakthrough-priority review; decision expected 2H-25.
- Interim two-year data (n=42) show 83 % of pivotal-trial patients retain 鈮�3-point rVCSS improvement, 74 % median pain reduction and 100 % valve patency (n=30).
- enVVe transcatheter valve finished GLP study; IDE submission targeted Q3-25.
- 19.2 m shares outstanding after exercising 1.7 m pre-funded warrants.
Key takeaways: Clinical results and regulatory momentum are constructive, but losses, cash draw and the absence of revenue keep financing risk on the table.
FAQ
What is the current stock price of Envveno Medical Corporation (NVNO)?
What is the market cap of Envveno Medical Corporation (NVNO)?
What is the primary focus of enVVeno Medical Corporation?
What are the company鈥檚 lead products?
How does enVVeno generate value through its product development?
What is the current regulatory status of enVVeno's products?
How do the VenoValve and enVVe devices function?
What differentiates enVVeno Medical from its competitors?
